Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Haematologica
|
May 30, 2013
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia
Clifton C Mo, Ndegwa Njuguna, Paul V Beum, et al.
Expert Opinion on Drug Safety
|
October 31, 2023
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
Shonali Midha, Monique A Hartley-Brown, Clifton C Mo, et al.
Ejhaem
|
August 21, 2023
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C Mo, Andrew J Yee, Shonali Midha, et al.
Expert Opinion on Emerging Drugs
|
October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data
Clifton C Mo, Yuxin Liu, Omar Nadeem, et al.
JMIR Research Protocols
|
December 19, 2024
Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial
Amber J Normann, Clifton C Mo, Rebekah L Wilson, et al.
Expert Review of Hematology
|
July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide
Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Clinical and Experimental Medicine
|
July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs
Xili Liu, Maria Moscvin, Seungeun Oh, et al.
Expert Opinion on Biological Therapy
|
March 17, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
Yuxin Liu, Ji Hyun Lee, Clifton C Mo, et al.
Blood Reviews
|
June 9, 2024
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide
Clifton C Mo, Edward Richardson, Eleonora Calabretta, et al.
Blood Advances
|
February 9, 2021
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
Katie Maurer, Anna Saucier, Haesook T Kim, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Haematologica
|
May 30, 2013
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia
Clifton C Mo, Ndegwa Njuguna, Paul V Beum, et al.
Expert Opinion on Drug Safety
|
October 31, 2023
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
Shonali Midha, Monique A Hartley-Brown, Clifton C Mo, et al.
Ejhaem
|
August 21, 2023
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C Mo, Andrew J Yee, Shonali Midha, et al.
Expert Opinion on Emerging Drugs
|
October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data
Clifton C Mo, Yuxin Liu, Omar Nadeem, et al.
JMIR Research Protocols
|
December 19, 2024
Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial
Amber J Normann, Clifton C Mo, Rebekah L Wilson, et al.
Expert Review of Hematology
|
July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide
Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Clinical and Experimental Medicine
|
July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs
Xili Liu, Maria Moscvin, Seungeun Oh, et al.
Expert Opinion on Biological Therapy
|
March 17, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
Yuxin Liu, Ji Hyun Lee, Clifton C Mo, et al.
Blood Reviews
|
June 9, 2024
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide
Clifton C Mo, Edward Richardson, Eleonora Calabretta, et al.
Blood Advances
|
February 9, 2021
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
Katie Maurer, Anna Saucier, Haesook T Kim, et al.
Page
of 3